Your Global Leader in Stem Cell Market Research
Stem cell clinical trials are research studies that involves human patients. Learn a simple tool to identify stem cell clinical trials for your condition.
Are you or a loved on suffering from arthritis, multiple sclerosis (MS), COPD, Alzheimer’s disease, asthma, or other chronic condition? If so, how do you find a stem cell clinical trial?
This article provides the answers, including links to find a clinical trials near you, as well as links to clinical trials for specific conditions.
As exosomes become recognized for their benefits as cell-free therapeutics, exosome clinical trials are increasing in number. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, altering the function of target cells.
In addition to increasing in number, exosome clinical trials are tightly concentrated within specific regions of the world.
There are now 92 trials listed on ClinicalTrials.gov that contain the term “exosome” or “exosomes.” [Read more…]
May 5, 2017, Melbourne, Australia — A private Australian biotechnology company called Exopharm has announced its investment to bring a completely new type of drug called exosomes into local clinical trials.
Exopharm is founded and backed by Dr Ian Dixon, the Melbourne-based technology innovator behind an ASX-listed cell therapy company, the anisina anticancer drug and the Altnia Group incubator. After more than 3 years of secret R&D, Altnia is spinning Exopharm out as a specialist company to translate the promising scientific research around exosomes into routine clinical use worldwide for regenerative medicine. Exopharm will build on its patented purification technology called LEAP to make its proprietary exomeres in large scale and at low cost. [Read more…]
Currently, there are a number of clinical trials that are investigating the therapeutic potential of mesenchymal stem cells derived from umbilical cord tissue, often called Wharton’s Jelly.
Specific conditions that have been or are now being researched for their potential to be treated with stem cells derived from cord tissue include:
Clinical trials currently listed as involving the use of cord-tissue derived mesenchymal stem cells include:
To search for more clinical trials using CT-MSCs, head to ClinicalTrials.gov and search for the following terms:
ClinicalTrials.gov is website maintained by the U.S. National Institutes of Health (NIH) that is a “registry and results database of publicly and privately supported clinical studies of human participants from around the world.” While an excellent resource, it does not include all clinical trials worldwide, including some which may be listed on international registries.
These searches will capture clinical trials that use varied vocabulary, as well as both singular and plural descriptions of the cell type. Other searches may be effective as well.
Mesenchymal stem cells (MSCs) can also be derived from other tissue sources besides the newborn umbilical cord.
Specifically, MSCs can be derived from adult sources that include adipose tissue, peripheral blood, and bone marrow, as well as from neonatal tissues that include parts of the placenta and umbilical cord, as explored in the image below. This is significant because pre-clinical and clinical advances with the use of MSCs derived from other sources than cord tissue will create a greater willingness to explore medical applications for cord tissue-derived MSCs.
IMAGE. SOURCES OF MESENCHYMAL STEM CELLS
BioInformant is the first and only market research firm to specialize in the stem cell industry. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.
In 2014, the International Federation for Cell Biology (IFCB) conducted an analysis of mesenchymal stem cell clinical trials, identifying that 313 clinical trials involved mesenchymal stem cells (MSCs). The majority of these clinical trials (41.7%) were in Phase I/II. Another 23.7% of these studies were in Phase II. However, only 4.2% of these clinical trials had progressed to Phase III. As such, it is clear that the bulk of MSC clinical trials remain in the early stages of development.
Among the clinical trials that progressed through Phase III, one of the most promising stem cell therapies to emerge was Prochymal, an allogenic mesenchymal stem cell therapy derived from the bone marrow of adult donors and made by Osiris Therapeutics. Prochymal is produced by purifying MSCs from the bone marrow of donors, then culturing and packaging the cells, allowing up to 10,000 doses to be derived from a single donor. [Read more…]
